FIRST-IN-HUMAN PHASE 1A STUDY OF NG-641, A TUMOUR-SELECTIVE VECTOR EXPRESSING A FAP-TAC BISPECIFIC ANTIBODY AND IMMUNE ENHANCER MODULE, IN PATIENTS WITH METASTATIC/ADVANCED EPITHELIAL TUMOURS (STAR) Meeting Abstract
Open Access
International Collaboration